Previous 10 | Next 10 |
home / stock / lexxw / lexxw news
(TheNewswire) Expands DehydraTECH™ B2B manufacturing capabilities to support Lexaria’s growing corporate customer base Lexaria to also receive royalty revenue from DehydraTECH product sales through BevNology’s commercial license rig...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced the awarding of a five-year, non-exclusive DehydraTECH(TM) license from its wholly-owned subsidiary, Lexaria Pharmaceutical Corp., to AnodGen Bioceuticals of Ireland. According to the u...
DehydraTECH Pharmaceutical License Issued for the European, Australian and New Zealand markets Lexaria to receive royalty revenue from DehydraTECH product sales KELOWNA, BC / ACCESSWIRE / June 8, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexar...
KELOWNA, BC / ACCESSWIRE / June 6, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce it has successfully filed a pre-Investigational New Drug ("IND") meeting request letter with the U...
(TheNewswire) Minimum payments due to Lexaria of US$4,527,500 over the first five years to retain exclusivity Lexaria to receive royalty revenue from DehydraTECH product sales Kelowna, British Columbia – TheNewswire - June 2, ...
KELOWNA, BC / ACCESSWIRE / June 1, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results of the 2022 Annual Meeting (the "Meeting"). On May 31, 2022 at 1:00 p.m. (Pacific Time), the Compa...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced its receipt of its first-ever patent for the use of DehydraTECH technology in the enhanced delivery of antiviral drugs. According to the update, Lexaria has received notification from t...
(TheNewswire) 25 th patent grant is Lexaria’s first-ever patent for the enhanced delivery of antivirals Kelowna, British Columbia – TheNewswire - April 21, 2022 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasda...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced that it has begun its multi-week human clinical hypertension study. The randomized, double blinded, placebo-controlled, cross-over study in 60 people, HYPER-H21-4, is the most comprehen...
(TheNewswire) HYPER-H21-4 will evaluate DehydraTECH TM -CBD for reducing blood pressure together with other potential clinical benefits This s tudy is designed to enhance Lexaria’s probabilities of success with its ...
News, Short Squeeze, Breakout and More Instantly...
Lexaria Bioscience Corp. Warrant Company Name:
LEXXW Stock Symbol:
NASDAQ Market:
Lexaria Bioscience Corp. Warrant Website:
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced the receipt of interim results from the first four weeks of dosing in its ongoing diabetes animal study WEIGHT-A24-1. The company noted that the results have already produced several notewort...
(TheNewswire) DehydraTECH appears to work with a second GLP-1 drug – liraglutide DehydraTECH appears to be working with semaglutide both with and without SNAC technology DehydraTECH-CBD is showing strong apparent performance relative to GLP-1 D...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, is preparing for growth by executing a strategic growth plan. A key element of the plan includes expanding the company’s management team to enable efficient handling of a greater workload of projects ...